Positioning of novel tumor marker NX-PVKA-R in the diagnosis of hepatocellular carcinoma in comparison with PIVKA-II by Kazuyoshi Suzuki et al.
INTRODUCTION
Protein induced by vitamin K absence or antagonist 
II （PIVKA-II） is an abnormal form of prothrombin 
produced in patients with vitamin K deficiency. In 
1984, Liebman et al. reported PIVKA-II as a novel tu-
mor marker in hepatocellular carcinoma （HCC）1）. With 
PIVKA-II, the 10 g-carboxyglutamic acid （Gla） resi-
dues near the N-terminal of factor II （prothrombin）, a 
vitamin K-dependent protein involved in blood coagu-
lation, are not synthesized normally, and all or some of 
the glutamic acid residues （Glu residues） appear in 
the blood without modification. Although highly specif-
ic to HCC, PIVKA-II shows false-positive results in 
the presence of vitamin K deficiency due to cholestasis 
or warfarin treatment.
PIVKA-II exists with 1-10 Glu residues, but con-
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SUMMARY
Background/Aims：To compare the use of protein induced by vitamin K absence or antagonist II （PIV-
KA-II） measured conventionally with the ratio between PIVKA-II measured using P-11 and P-16 antibod-
ies （NX-PVKA） and PIVKA-II measured conventionally （NX-PVKA-R） in terms of false-positive results 
for hepatocellular carcinoma （HCC）. Methodology：Subjects comprised 318 patients with chronic liver dis-
ease, including 8 patients receiving warfarin treatment, which can result in false-positive results for HCC. 
HCC was present in 65 patients （HCC group） and absent in 253 （non-HCC group）. PIVKA-II was mea-
sured conventionally. NX-PVKA-R was calculated as PIVKA-II/NX-PVKA. Results：Both PIVKA-II and 
NX-PVKA-R were significantly higher in the HCC group than in the non-HCC group （p＜0.0001 each）. 
False-positive results were seen in 9.5％ of non-HCC patients with PIVKA-II, and in 10.3％ with NX-PV-
KA-R. False-positive results were seen for all 8 patients （100％） on warfarin with PIVKA-II, but for 0％ 
with NX-PVKA-R. Sensitivity, specificity, and accuracy were all lower for NX-PVKA-R than PIVKA-II. 
Conclusions：NX-PVKA-R is not more useful than PIVKA-II for diagnosing HCC, but is very useful in 
subpopulations such as patients on warfarin and patients with jaundice. The characteristics of NX-PVKA-R 
can be best exploited by selecting patients in which these factors are present.
Key Words： protein induced by vitamin K absence or antagonist II （PIVKA-II）；NX-PVKA-R；hepato-
cellular carcinoma
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warfarin treatment.
The cause of liver disease was hepatitis B virus 
（HBV） in 39 patients, hepatitis C virus （HCV） in 226 
patients, HBV＋HCV in 2 patients, excessive alcohol 
consumption in 22 patients, and other causes in 29 pa-
tients. HCC was diagnosed using dynamic computed 
tomography （CT） or digital-subtraction angiography 
（DSA）. HCC was present in 65 patients and absent in 
253 （Table 1）. HCC tumor factors are shown in Table 
1 , but due to the small number of patients in this 
study, relationships between HCC tumor stage and 
PIVKA-II and NX-PVLA-R were not examined. All 8 
patients on warfarin were without HCC.
Measurement of PIVKA-II and NX-PVKA
PIVKA-II was measured using the Picolumi PIV-
KA-II （cut-off, 40 mAU/ml；Eidia, Tokyo, Japan） 
method4）. This method employs mouse anti-human 
PIVKA-II antibody MU-3 and rabbit anti-human pro-
thrombin polyclonal antibody.
NX-PVKA was measured using sandwich electro-
chemiluminescence immunoassay. This method em-
ploys novel mouse anti-human PIVKA-II monoclonal 
antibodies P11 and P16 （Sekisui Medical, Tokyo, Ja-
pan）, generated by immunization with PIVKA-II from 
a warfarin user3）. NX-PVKA-R was calculated as PIV-
KA-II/NX-PVKA.
ventional HCC diagnosis uses a monoclonal antibody 
（MU-3 antibody） that is highly reactive to types of 
PIVKA-II containing larger numbers of Glu residues2）. 
When the MU-3 antibody is used, discriminating be-
tween PIVKA-II induced by HCC and PIVKA-II 
caused by vitamin K deficiency is difficult. On the oth-
er hand, monoclonal antibodies that are highly reactive 
to PIVKA-II containing a small number of Glu resi-
dues have been developed （P-11 and P-16 antibod-
ies）, so using the ratio between PIVKA-II measured 
using these antibodies （NX-PVKA） and the conven-
tional measurement of PIVKA-II （NX-PVKA-R） al-
lows the elimination of false-positive results due to vi-
tamin K deficiency resulting from factors such as 
warfarin treatment3）.
This study examined the usefulness of NX-PVKA-R 
in the diagnosis of HCC in comparison to the conven-
tional use of PIVKA-II alone.
METHODOLOGY
Patients
Subjects comprised 318 patients with chronic liver 
disease who consulted the Department of Gastroenter-
ology at Dokkyo Medical University Koshigaya Hospi-
tal between March and September 2011 . These pa-
tients included 21 patients with jaundice with a total 
bilirubin level ≥ 2 .0 mg/dl, and 8 patients receiving 
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Table 1　Ckinical characteristics of 318 patients
HCC （n＝65） non HCC （n＝253）
Sex （M：F） 42：23 143：110
Age（mean±SD） 72.5±10.0 65.2±12.0
Cause of liver disease HBV 9 HBV 30
HCV 42 HCV 184
HBV＋HCV 1 HBV＋HCV 1
Alcohol 5 Alcohol 17
NASH 2 AIH 2
Other 6 PBC 5
Willson 1
Other 13
Tumor factors
　　Size（mean±SD cm） 4.2±3.5
　　Number（single：multiple） 25：40
　　Venous invasion（＋：−） 8：57
　　Distant metastasis （＋：−） 1：64 　 　
HBV, hepatitis B virus；HCV, hepatitis C virus；NASH, non alcoholic steatohepatitis
AIH, autoimmun hepatitis；PBC, primary biliary cirrhosis；Wilson, Wilson’s desease
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Comparison of PIVKA-II and NX-PVKA-R
PIVKA-II and NX-PVKA-R values for the 65 pa-
tients in the HCC group and the 253 patients in the 
non-HCC group were shown in Figure 2 . The HCC 
group presented significantly higher values （p＜
0.0001） for both PIVKA-II （Figure 2a） and NX-PV-
KA-R （Figure 2b）. PIVKA-II yielded false-positive 
results in 24 of 253 patients in the non-HCC group 
（9.5％）, and NX-PVKA-R yielded false-positive re-
sults in 26 of these patients （10.3％）.
Figure 3 shows PIVKA-II and NX-PVKA-R values 
for the 8 patients without HCC who were on warfarin. 
PIVKA-II yielded false-positive results for all 8 pa-
tients, but NX-PVKA-R showed values below the cut-
Clinical parameters
Blood biochemical parameters as hepatitis activity, 
liver residual function, and liver fibrosis, serum alanine 
aminotransferase （ALT） levels, serum total bilirubin, 
albumin concentrations, platelet cell count, and pro-
thrombin activity （PT％） were measured. After ap-
proval by the Institution Review Board of Dokkyo 
Medical University Koshigaya Hospital, the present 
study was conducted only after written informed con-
sent was obtained from the patients.
Statistical analysis
Continuous data are expressed as mean±standard 
deviation （SD）. The Mann-Whitney U test was used 
in comparisons between two groups. Values of p＜0.05 
were regarded as statistically significant.
RESULTS
Clinical parameters of HCC groups and non-HCC 
group
Blood biochemical parameters of patients in the 
group with HCC （HCC group） and the group without 
HCC （non-HCC group） were shown in Table 2 . No 
significant differences between groups were seen with 
respect to ALT, total bilirubin, albumin concentration, 
or platelet count, but PT％ was significantly higher in 
the non-HCC group.
Cutt-off valur of NX-PVKA-R
Figure 1 shows the receiver operating characteristic 
（ROC） curve for NX-PVKA-R. Using this curve, 1.28 
was calculated as the cut-off value maximizing the 
Youden index. Significant figures for NX-PVKA-R 
were considered to be those figures up to one decimal 
place, so the cut-off value was rounded to 1.3, and this 
value was used in subsequent calculations.
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Table 2　Clinical parameters of 318 patients
HCC （n＝65） non HCC （n＝253） t-test
ALT （IU/L） 46.1±31.8 44.5±47.4 P＝0.307
T-Bil （mg/dL） 1.2±1.1 1.2±2.6 P＝0.283
Alb （g/dLl） 3.5±0.6 4.0±0.6 P＝0.819
PT （％） 93.7±14.2 98.2±21.5 P＝0.006
Platelet （×104/mL） 12.0±7.8 14.1±7.5 P＝0.286
ALT, alanine aminotransferase；T-Bil, total bilirubin；Alb, albumin；PT （％）, 
prothrombinnactivity
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Figure 1　 The receiver operating characteristic （ROC） 
curve for NX-PVKA-R. Using this curve, 1.28 
was calculated as the cut-off value maximizing 
the Youden index. Significant figures for 
NX-PVKA-R were considered to be those 
figures up to one decimal place, so the cut-off 
value was rounded to 1.3, and this value was 
used in subsequent calculations.
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The sensitivity, specificity and accuracy of PIVKA-
II and NX-PVKA-R were calculated, and shown in 
Table 3. Sensitivity, specificity, and accuracy were all 
lower for NX-PVKA-R than PIVKA-II.
off point for all patients. Figure 4 shows PIVKA-II and 
NX-PVKA-R values for the 21 jaundice patients with 
total bilirubin levels ≥ 2 .0 mg/dL. PIVKA-II yielded 
false-positive results for 9 of the 17 patients without 
HCC （52 .9％）, whereas NX-PVKA-R showed false 
positives for 3 patients （17.6％）.
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Figure 2　 PIVKA-II and NX-PVKA-R values for the 65 patients in the HCC group and the 253 patients in the non-
HCC group. The HCC group presented significantly higher values （p＜0.0001） for both PIVKA-II （Fig. 2a） 
and NX-PVKA-R （Fig. 2b）.
a b
Figure 3　 PIVKA-II and NX-PVKA-R values for the 8 
patients without HCC who were on warfarin. 
PIVKA-II yielded false-positive results for all 8 
patients, but NX-PVKA-R showed values 
below the cut-off point for all patients.
Figure 4　 PIVKA-II and NX-PVKA-R values for the 21 
jaundice patients with total bilirubin levels 
≥ 2.0 mg/dL. PIVKA-II yielded false-positive 
results for 9 of the 17 patients without HCC 
（52.9％）, whereas NX-PVKA-R showed false 
positives for 3 patients （17.7％）.
Positioning of NX-PVKA-R
forms of PIVKA-II with 5-10 Gla residues 16）. The 
monoclonal antibodies used to measure NX-PVKA in 
the present study （P-11 and P-16 antibodies） are 
highly reactive to types of PIVKA-II containing only a 
small number of Glu residues. Toyoda et al. measured 
and compared PIVKA-II and NX-PVKA values in 20 
patients with HCC and 56 patients without HCC on 
warfarin. PIVKA-II showed no significant difference 
between groups （p＝0 .7952）, but patients without 
HCC on warfarin presented significantly higher values 
for NX-PVKA （p＝0.0291）. NX-PVKA-R showed sig-
nificantly higher values in patients with HCC than in 
patients without HCC on warfarin （p＜0.0001）. Based 
on those results, NX-PVKA-R has been reported to 
identify patients on warfarin with elevated PIVKA-II 
due to HCC and is useful as a tumor marker for HCC 
in this patient subpopulation3）. Although Toyoda et al. 
proposed 1 . 5 as the optimal cut-off value for NX-
PVK-R in those studies, we independently created an 
ROC curve for our study, and used a cut-off of 1.3. In 
the future, further research with greater numbers of 
patients will be needed to assess the validity of this 
cut-off value.
Our study compared the usefulness of PIVKA-II 
and NX-PVKA-R for diagnosing HCC in 318 patients 
with chronic liver disease. Although only 8 patients 
were on warfarin, representing a small sample size, 
false-positive results were able to be eliminated for 
HCC diagnosis in all 8 patients. In addition, false-posi-
tive results were also able to be eliminated in 18 of 21 
patients （82 .4％） with jaundice resulting from im-
paired vitamin K absorption due to cholestasis. Al-
though separate data are not presented here, the pres-
ent findings suggest that NX-PVKA-R might be 
useful in alcoholic liver disease. The above findings 
once again confirmed the usefulness of NX-PVKA-R 
in the diagnosis of HCC in vitamin K-deficient patients.
Conversely, false-positive HCC diagnoses were seen 
in about 10％ of cases with both PIVKA-II and NX-
PVKA-R. Patients presenting false positives for PIV-
DISCUSSION
The process by which prothrombin is synthesized in 
the liver first produces a precursor with 10 Glu resi-
dues in the Gla domain. This precursor is then re-
leased into the blood as an active coagulation factor 
through conversion of Glu residues to Gla residues by 
g-glutamylcarboxylase （GGCX） in the presence of the 
reduced form of vitamin K, O2, and CO2. However, if a 
vitamin K deficiency is present or the patient is taking 
a vitamin K antagonist during this process, g-carboxy-
lation will not proceed normally, and several of the 10 
Glu residues will remain, producing a prothrombin 
lacking blood-coagulating activity. This is called des-
g-carboxyprothrombin or PIVKA-II.
PIVKA-II is not only used for diagnosis of HCC, but 
also correlates with portal venous invasion of HCC5）, 
and is reportedly a factor that reflects tumor stage 
and survival rate in HCC6）. PIVKA-II is also produced 
by non-cancerous tissues surrounding HCC7, 8）, and 
works not only as a growth factor for HCC9〜11）, but 
also as a vascular endothelial growth factor for HCC, 
and is believed to play an important role in angiogene-
sis12,13）.
As discussed above, PIVKA-II is a very useful tu-
mor marker in the diagnosis and prognosis prediction 
of HCC. However, PIVKA-II levels are also elevated in 
patients with vitamin K deficiency, such as those on 
warfarin, and in end-stage liver disease patients with-
out HCC14）. False-positive results can therefore be 
problematic. On the other hand, various types of PIV-
KA-II exist, based on the number of Glu residues pres-
ent, and the types of PIVKA-II in patients taking vita-
min K antagonists reportedly differ from those in 
patients with HCC1,15）. In addition, the reagent for 
measuring PIVKA-II that is currently widely used in 
Japan （Picolumi PIVKA-II；Eidia） uses a monoclonal 
antibody obtained from the MU-3 cell line. This re-
agent is highly reactive to PIVKA-II that contains a 
large number of Glu residues, but does not react with 
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Table 3　Sensitivity, specificity and accuracy of PIVKA-II and NX-PVKA-R
　 Cut off Value Sensitivity Specificity Accuracy
PIVKA-Ⅱ 40 mAU/mL 74.2％ 92.8％ 89.0％
NX-PVKA-R 1.3 63.4％ 89.2％ 83.9％
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KA-II were patients on warfarin, jaundice patients 
and heavy drinkers, but, as discussed above, false posi-
tives caused by these factors can be avoided using 
NX-PVKA-R. Furthermore, one of the reasons false 
positives for NX-PVKA-R were present for about 10
％ of patients was presumably the tendency for NX-
PVKA-R to show high levels when PIVKA-II values, 
as the numerator, are low. When the sensitivity, speci-
ficity and accuracy according to eventual HCC diagno-
sis were examined, better results were obtained in 
each case for PIVKA-II than for NX-PVKA-R.
CONCLUSIONS
NX-PVKA-R is not more useful than PIVKA-II for 
diagnosing HCC, but is very useful in subpopulations 
such as patients on warfarin, patients with jaundice, 
and the characteristics of NX-PVKA-R can be fully 
exploited by selecting those patients in which these 
factors are present.
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